Cutting-Edge Cancer Care
We are thrilled to announced that ECHO has enrolled the first patient in the world into a new clinical trial. The trial is for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed while receiving maintenance immunotherapy. The trial will compare a new therapeutic cancer vaccine to previous standard of care.
Previously, patients who have progressed with immunotherapy were left with few choices. Now, with cutting edge treatments, there are promising new avenues.
What are Cancer Vaccines?
Cancer vaccines are a form of immunotherapy that can help educate the immune system about what cancer cells “look like” so that it can recognize and eliminate them. Cancer vaccines are tailored to the specific genetic mutations found in an individual’s cancer.
Cancer vaccine trials are ongoing research studies aimed at developing new vaccines to prevent or treat cancer. These trials investigate the safety, efficacy, and potential benefits of different vaccine formulations.
About the ECHO Study
This is a randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA study
The usual treatment for patients who progress is second line chemotherapy, docetaxel (with or without ramucirumab). This trial compares a therapeutic cancer vaccine to the standard of care docetaxel. Initially patients will be tested for HLA-A2 positivity. If patients are HLA-A2 positive, they will be invited to participate in the clinical trial and then participate in the screening process. If patient meet the inclusion criteria, they are randomized to receive either docetaxel or the therapeutic cancer vaccine.
Who Can Participate
This trial is for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed while receiving maintenance immunotherapy [Keytruda (pembrazolimab, Opdivo, (nivolumab), Imfinzi (durvalumab) or Tecentriq (atezolizumab)]. The initial process after consenting to participate in the prescreening portion of the trial is to determine if the patient is HLA-A2 positive. This is determined through a blood test.
- Click here to learn about ECHO’s current clinical trials,
- Click here to find out what it means to participate in a clinical trial.
- To learn more about clinical trials, please contact Dr. Susan Johnson, Director of Research sjohnson@echoct.com or 860-886-8362.